Loading...
XLONOBD
Market cap5mUSD
Dec 24, Last price  
1.30GBP
1D
11.11%
1Q
-58.73%
Jan 2017
-99.14%
IPO
-99.19%
Name

Oxford Biodynamics PLC

Chart & Performance

D1W1MN
XLON:OBD chart
P/E
—
P/S
806.96
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
10.95%
Rev. gr., 5y
-15.53%
Revenues
510k
+231.17%
350,000659,000702,0001,091,0001,183,0001,186,000907,000456,000341,000154,000510,000
Net income
-11m
L+61.34%
-1,055,000-736,000-1,005,000-1,730,000-3,804,000-1,953,000-2,800,000-4,313,000-6,682,000-6,710,000-10,826,000
CFO
-8m
L+62.95%
190,000-424,000-1,229,000-1,348,000-1,526,000-1,942,000-2,271,000-3,401,000-5,918,000-5,177,000-8,436,000
Earnings
Jan 15, 2025

Profile

Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
URL
https://www.oxfordbiodynamics.com/
IPO date
Dec 06, 2016
Employees
43
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
510
231.17%
154
-54.84%
Cost of revenue
4,413
3,016
Unusual Expense (Income)
NOPBT
(3,903)
(2,862)
NOPBT Margin
Operating Taxes
(585)
(857)
Tax Rate
NOPAT
(3,318)
(2,005)
Net income
(10,826)
61.34%
(6,710)
0.42%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,387
3,623
BB yield
-28.20%
-31.60%
Debt
Debt current
818
736
Long-term debt
12,060
11,536
Deferred revenue
Other long-term liabilities
440
424
Net debt
7,628
11,273
Cash flow
Cash from operating activities
(8,436)
(5,177)
CAPEX
(250)
(901)
Cash from investing activities
(691)
1,251
Cash from financing activities
13,420
2,562
FCF
(2,317)
(1,775)
Balance
Cash
5,250
999
Long term investments
Excess cash
5,224
991
Stockholders' equity
(28,802)
(16,432)
Invested Capital
41,736
25,519
ROIC
ROCE
EV
Common stock shares outstanding
147,482
99,702
Price
0.37
221.74%
0.12
-74.01%
Market cap
54,568
375.92%
11,466
-72.01%
EV
62,196
22,739
EBITDA
(2,546)
(1,649)
EV/EBITDA
Interest
213
195
Interest/NOPBT